SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 10, 2014--
Exelixis, Inc. (NASDAQ: EXEL) will release its fourth quarter and full
year 2013 financial results on Thursday, February 20, 2014 after the
markets close. The announcement will be followed by a live webcast at
5:00 p.m. EST/ 2:00 p.m. PST. During the webcast, Exelixis management
will discuss the Company's financial results, financial outlook and
development program and plans for cabozantinib, and also provide a
general business update. The webcast may be accessed in the Event
Calendar page under Investors & Media at www.exelixis.com.
An archived replay of the webcast will be available on the Event
Calendar page under Investors & Media at www.exelixis.com
and via phone until 11:59 p.m. EST on March 20, 2014. Access numbers for
the phone replay are: 888-286-8010 (domestic) and 617-801-6888
(international); the passcode is 59600043.
About Exelixis
Exelixis is a biotechnology company committed to developing small
molecule therapies for the treatment of cancer. Exelixis is focusing its
proprietary resources and development efforts exclusively on COMETRIQ®
(cabozantinib). Exelixis has also established a portfolio of other novel
compounds that it believes have the potential to address serious unmet
medical needs, many of which are being advanced by partners as part of
collaborations. For more information, please visit the company's web
site at www.exelixis.com.
Exelixis, the Exelixis logo, and COMETRIQ are registered U.S.
trademarks.
Source: Exelixis, Inc.
Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President,
Investor Relations and Corporate Communications
cbutler@exelixis.com